AI Workers Smoking to Demonstrate Faith in Technology, Palantir CTO Claims

Some artificial intelligence researchers have adopted the habit of smoking cigarettes as a symbolic gesture to demonstrate their profound belief in AI's potential to mitigate health risks, including those associated with smoking, according to Shyam Sankar, Chief Technology Officer at Palantir.

In a recent interview with CBS, Sankar explained this unusual trend, stating, "So many AI researchers have started smoking as a way of signaling to other researchers how much they believe in AI." He elaborated on this phenomenon, suggesting it reflects a deep-seated trust in the technology to eventually offer solutions to its own detrimental effects. "‘I believe so much in AI that it’s going to cure cancer. So I’m showing you my chips are all in,'" Sankar said, characterizing the behavior as a form of "mass psychosis" and "social delusion." He posited that for some in Silicon Valley, AI has become a surrogate for a "God-shaped hole" in their lives.

These remarks surface amidst ongoing discussions about the future of AI, particularly following stark warnings from a former Anthropic employee. Jacob Coxon, who resigned from the AI company, told NBC News that there is a "substantial probability that this technology could kill everyone," emphasizing that his concerns were not hyperbole or a marketing tactic.

Coxon's statements have led to calls from some AI leaders for a more cautious approach to AI development. However, the Trump administration has dismissed such fears, characterizing them as a "hoax." The administration's stance appears to be influenced by the philosophy of "effective accelerationism," which posits that rapid AI development is crucial for humanity's benefit and that any slowdown would be detrimental.

The potential benefits of AI, particularly in healthcare, are a significant aspect of the accelerationist viewpoint. Researchers are exploring AI's capabilities in areas such as personalized medicine, mental health treatment, and even cancer cures.

For instance, a recent development in melanoma treatment highlighted AI's role. Moderna and Merck announced a significant milestone in the testing of a melanoma vaccine. This trial, involving 1,100 patients, utilized AI to analyze individual tumor data, enabling the creation of highly personalized vaccines. AI's capacity to process vast datasets—spanning decades of research, case studies, and clinical trials—is seen as a key advantage in accelerating medical breakthroughs. Dr. David Fajgenbaum, co-founder of the AI-driven non-profit Every Cure, noted, "We utilize the world’s knowledge, rather than relying only on what is in our brains."